You started a peptide protocol and it worked. Sleep improved, energy returned, skin looked better. Then, around week eight or ten, the effects seemed to plateau. The dose didn't change. The product didn't change. But the response did. This is receptor desensitization — and it's the reason cycling matters.
The biology of tolerance
When a peptide binds to its receptor, it triggers a cellular response. That's how the drug works. But cells are adaptive — when a receptor is stimulated continuously, the cell can respond in several ways to reduce its sensitivity to the signal:
Receptor internalization. The cell pulls receptors off its surface, reducing the number available for the peptide to bind. Fewer receptors means a weaker response to the same dose.
Receptor downregulation. The cell reduces the production of new receptors. Over time, the total receptor population on the cell surface declines.
Downstream signal attenuation. Even when the peptide binds successfully, the intracellular signaling cascade it triggers becomes less robust. The machinery gets tired.
These aren't failures of the peptide — they're your body's homeostatic response to sustained stimulation. The cell is trying to return to equilibrium. Understanding this reframes the "my peptide stopped working" complaint: it didn't stop working. Your body adapted to it working.
Which peptides are most affected
GH secretagogues (Sermorelin, CJC-1295/Ipamorelin, MK-677) are the most commonly cited candidates for cycling. The GHRH and ghrelin receptors can desensitize with continuous stimulation, leading to progressively lower GH output at the same dose. This has been observed clinically and is consistent with receptor pharmacology.
PT-141 targets melanocortin receptors, which are known to desensitize with frequent stimulation. The FDA-approved label for Vyleesi limits use to 8 doses per month, partly for this reason.
BPC-157 has a less clear-cut desensitization profile. Many clinicians use it for defined periods (4-8 weeks for a healing goal) rather than cycling it on/off indefinitely. Whether BPC-157's receptor dynamics require cycling in the same way as GH secretagogues is not established.
GHK-Cu influences gene expression through a different mechanism than classical receptor binding. Whether cycling improves outcomes with GHK-Cu is uncertain — some clinicians recommend continuous use during a skin or hair protocol, while others cycle it as a general principle.
Common cycling patterns
Weekly micro-cycling (5/2): Five days on, two days off. This maintains near-continuous effect while providing brief receptor recovery windows. Most commonly used for GH secretagogues in maintenance protocols. The two off-days are typically weekends, for convenience rather than pharmacological reasons.
Block cycling (8-12 weeks on / 4 weeks off): A longer use period followed by a meaningful rest period. This is preferred when the goal is to achieve a specific outcome (healing, body composition change) and then reassess. Lab monitoring (IGF-1 for GH secretagogues, metabolic panel for metabolic peptides) during the off period provides data on how your body performs without the peptide.
Goal-based cycling: Use the peptide for a defined purpose and duration, then stop. BPC-157 for post-surgical healing (4-8 weeks), TB-500 for a tendon injury (6-12 weeks), GHK-Cu for a skin protocol before a specific event (8 weeks). This isn't cycling in the traditional sense — it's purposeful use with a defined endpoint.
Signs a cycle break may be needed
Pay attention to diminishing subjective response. If your GH secretagogue initially improved sleep quality noticeably and that improvement has faded while your dose and timing haven't changed, receptor adaptation is the likely explanation.
Lab markers can also signal adaptation. A plateau in IGF-1 levels despite continued GH secretagogue use suggests the pituitary response is attenuating. This is the most objective way to monitor tolerance — and the best reason to work with a provider who monitors labs during a protocol.
Increasing your dose to chase the initial effect is the wrong response. Dose escalation accelerates receptor desensitization and increases side effect risk. The right response is a rest period, followed by a return to the original dose.
What a rest period actually does
During the off period, cells re-express receptors on their surfaces, restore receptor populations to baseline levels, and normalize downstream signaling sensitivity. How long this takes varies by receptor type and individual biology, but 2-4 weeks is sufficient for most peptide receptors to substantially recover.
The practical experience confirms this: women who take a planned break from GH secretagogues and return often report that the initial effects return at the original dose — improved sleep, better recovery, subjective energy — validating that receptor resensitization occurred during the break.
Cycling is not a failure of the protocol. It's part of the protocol. Build it in from the start, monitor your response, and let your body's feedback guide the specifics.